Idiosyncratic drug-induced liver injury (DILI) is an unexpected, dose independent reaction that can occur without warning after exposure to a medication. This type of liver injury is not predictable, and it appears to be dependent on multiple factors such as age, sex and genetic polymorphisms of drug metabolizing enzymes such as cytochrome P450. Fluoxetine is associated with an asymptomatic increase in liver enzymes in 0.5% of the cases but is rarely associated with either FHF or SJS. 8, 9 There is only a handful of case reports of isolated fluoxetine-induced DILI presenting as an acute hepatitis, but no reported cases of concomitant symptomatic DILI with SJS. 9-11 We present the first described case of fluoxetine-induced SJS and DILI.
protection. Physical examination was also notable for conjunctival injection, a generalized morbiliform rash involving 8% of the body surface area, and mucosal erosions in the oral cavity ( Figure 1 ). She also had a positive Nikolsky's sign.
She had marked scleral icterus and tender hepatomegaly. Her laboratory tests on admission were significant for total bilirubin of 3.5 mg/dL, direct bilirubin 2.6 mg/dL, AST 7078 U/L, ALT 1613 U/L, LDH 5308 U/L, ALP 160 U/L, GGT351 U/L, albumin 2.8 g/dL and INR of 2.42, with presumably normal baseline tests. Her acetaminophen level was 13.1 μg/mL, and urine toxicology screen was negative.
Ultrasound of the liver revealed hepatomegaly with steatosis but no ductal dilation and a normal appearing gallbladder.
Interestingly, 2 weeks prior to this presentation, she visited the emergency department for symptoms of fever and myalgia and was prescribed acetaminophen for a presumed viral illness.
On her first day of admission, the patient was treated with Nacetylcysteine (NAC) at 6 mg/kg/d for a total of 7 days for her abnormal liver function tests. She was monitored in the intensive care unit for concern of possible progression to FHF. Fluoxetine and all other potentially toxic medications were stopped on admission.
Serological tests for infectious pathology were negative for 
| WHAT IS NE W AND CON CLUS I ON
Drug-induced liver injuries is a rare clinical entity, categorized as either intrinsic or idiosyncratic. Intrinsic reactions are predictable, dose-related reactions, temporally related to medications and commonly seen when they exceed therapeutic doses. Idiosyncratic reactions have a non-temporal relationship and are dose independent.
1 Drug-induced skin reactions can present in its mild form of erythema multiforme to severe conditions such as SJS and TEN with mortality ranging from 10% to 50%. SJS and TEN are on the same spectrum with the similar underlying aetiology. However, the total body surface area (BSA) involved in SJS is by definition <10% BSA and >30% in TEN. When patients have an involved BSA between 10% and 30%, it is described as SJS/TEN overlap syndrome. 5, 6 The diagnosis of DILI and skin reactions is a clinical one; a thorough history, exclusion of other causes of liver and skin injury and probability of the suspected medication are factors to make a diagnosis. 1, 6 The algorithm of drug causality for epidermal necrolysis (ALDEN) score is specific to finding the likelihood of causality between drug and SJS/TEN. It factors in the duration between drug initiation and onset of symptoms, half-life of medication, information on commonly implicated drugs and effects of re-challenge, calculating the likelihood from "very unlikely," "unlikely," "possible, "probable" or "very probable". The calculated ALDEN score was three in our patient without incorporating any points for re-challenge which makes fluoxetine the "possible" cause of SJS. 12 Similarly, causality assessment tools such as Roussel-Uclaf Causality Assessment Method (RUCAM) 13, 14 and Naranjo Adverse Drug Reactions Probability Scale (NADRPS) 15 can be used to establish a relationship between a potentially hepatotoxic medication and liver injury. The RUCAM uses information such as the time to onset of liver injury, course of illness, risk factors according to the pattern of injury, concomitant use of possible hepatotoxic medications, consideration of other potential non-drug causes, known information on the potential hepatotoxicity of the drug and lastly, response to re-challenge of the drug (if the patient is re-challenged) to derive a standardized score. 13 To calculate the NADRPS, less information is used than the RUCAM scale. A study by Garcia-Cortes et al showed that NADRPS lacked validity, reproducibility and had lower sensitivity compared to RUCAM.
14,15
Therefore, we used the RUCAM to find fluoxetine "highly suggestive" as the cause of this patient's DILI. In addition, she had greater than a 50% decrease in her ALT levels within 8 days of ceasing the medication, which is also suggestive of causality. This patient also presented with the characteristic prodrome of SJS with flu-like symptoms, fevers and myalgia; however, it was unrecognized when she initially was seen in the emergency department.
Medications are the most commonly cited cause for SJS/TEN and DILI. Among antidepressants, selective serotonin reuptake inhibitors (SSRIs) are the most widely prescribed class, with fluoxetine being the most prescribed within its class. It acts by inhibiting the reuptake of 5-hydroxytryptamine in the central nervous system. It is metabolized by the cytochrome P450 system in the liver but is unclear whether fluoxetine or its toxic metabolites are the mediators of hepatotoxicity. 8, 16 Particular individuals appear to be more susceptible to these reactions for unclear reasons, but it is hypothesized that a combination of a genetic predisposition along with an environmental trigger must be present. A recent study revealed carbamazepine-induced SJS/ TEN was associated with HLA-B*5801 in a Han-Chinese population which supports the historical notion that a genetic predisposition could be foundational to the process. 6, 17 This is the subject of ongoing research, and there might be evidence linking fluoxetine and HLA in the near future.
The skin and liver are the most common organs affected by drug reactions. In a retrospective study of 748 patients with DILI, only 36 cases had both SJS with DILI (4.8%), and it was associated with a higher mortality rate of 22%. Patients affected were typically young females, and only a small number of "high-risk" drugs such as antiepileptic agents, sulphonamides and antiretroviral drugs accounted for the majority of cases. 7 The Drug-Induced Liver Injury Network recently described four deaths among nine patients with concomitant SJS and DILI in a cohort of 889 patients. 18 Despite the widespread use of antidepressants, SSRI-induced SJS/TEN and DILI is not commonly seen making our case unusual.
| CON CLUS ION
A commonly prescribed medication like fluoxetine can be associated with serious adverse effects. Clinicians should have a high level of suspicion for pharmaceuticals as a cause of abnormal liver enzymes or new skin manifestations, and all potentially offending medications should be stopped immediately. In addition to a good history and thorough serological workup, the Roussel-Uclaf Causality F I G U R E 3 Liver biopsy shows vesicular steatosis and steatohepatitis
